| __timestamp | Incyte Corporation | Teva Pharmaceutical Industries Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 165772000 | 5078000000 |
| Thursday, January 1, 2015 | 196614000 | 4717000000 |
| Friday, January 1, 2016 | 303251000 | 5096000000 |
| Sunday, January 1, 2017 | 366406000 | 4986000000 |
| Monday, January 1, 2018 | 434407000 | 4214000000 |
| Tuesday, January 1, 2019 | 468711000 | 3806000000 |
| Wednesday, January 1, 2020 | 516922000 | 3671000000 |
| Friday, January 1, 2021 | 739560000 | 3528000000 |
| Saturday, January 1, 2022 | 1002140000 | 3445000000 |
| Sunday, January 1, 2023 | 1161300000 | 3498000000 |
| Monday, January 1, 2024 | 1242157000 | 3702000000 |
Data in motion
In the ever-evolving pharmaceutical industry, understanding operational efficiency is crucial. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Teva Pharmaceutical Industries Limited and Incyte Corporation from 2014 to 2023. Over this period, Teva's SG&A expenses have shown a downward trend, decreasing by approximately 31% from 2014 to 2023. In contrast, Incyte's expenses have surged by over 600%, reflecting its aggressive growth strategy.
Teva, a global leader in generic medicines, has been optimizing its operations, evident from its reduced SG&A costs. Meanwhile, Incyte, known for its innovative therapies, has been investing heavily in its administrative and sales functions to support its expansion. This divergence in SG&A trends highlights the distinct strategic paths these companies are taking in a competitive market. Understanding these trends provides valuable insights into their operational priorities and market positioning.
Cost Management Insights: SG&A Expenses for Amgen Inc. and Teva Pharmaceutical Industries Limited
Breaking Down SG&A Expenses: argenx SE vs Teva Pharmaceutical Industries Limited
Comparing SG&A Expenses: Teva Pharmaceutical Industries Limited vs Ultragenyx Pharmaceutical Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for Teva Pharmaceutical Industries Limited and CRISPR Therapeutics AG
Teva Pharmaceutical Industries Limited vs Arrowhead Pharmaceuticals, Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Teva Pharmaceutical Industries Limited or Supernus Pharmaceuticals, Inc.
Genmab A/S and Incyte Corporation: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: Incyte Corporation vs Pharming Group N.V.
SG&A Efficiency Analysis: Comparing Incyte Corporation and ADMA Biologics, Inc.
Operational Costs Compared: SG&A Analysis of Incyte Corporation and Merus N.V.
Who Optimizes SG&A Costs Better? Incyte Corporation or Travere Therapeutics, Inc.
Incyte Corporation and MiMedx Group, Inc.: SG&A Spending Patterns Compared